The volume of generic drug products consumed by the Mexican population grew from 54% to 84% in the last three years, was announced by Mikel Arriola, Commissioner for the COFEPRIS, the Mexican regulatory agency. The announcement was made at the opening of a training session on marketing authorization of allopathic medicines of the Interchangeable Generic Drug Product Manufacturers Mexican Association (Asociación Mexicana de Fabricantes de Medicamentos Genéricos Intercambiables – AMEGI).
Dr. Arriola highlighted that Mexico is a the world leader in generic drug consumption, and that the Mexican people has overcome the myth that generic products are of poorer quality, safety and efficacy profile than those offered by innovative brands. He also mentioned that, thanks to expedite approval of these products, considerable savings are possible, both of out-of-pocket medicines expenditure, and public healthcare costs. Generic products now represent 52% of market share, the remaining 48% corresponding to innovatives.
View original post 163 more words
DRUG REGULATORY AFFAIRS INTERNATIONAL 